{
    "clinical_study": {
        "@rank": "90543", 
        "arm_group": [
            {
                "arm_group_label": "Lamazym", 
                "arm_group_type": "Active Comparator", 
                "description": "1 mg Lamazym/kg body weight"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective of this trial is to evaluate the efficacy and safety of repeated\n      Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with\n      alpha-Mannosidosis"
        }, 
        "brief_title": "A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alpha-Mannosidosis", 
        "condition_browse": {
            "mesh_term": [
                "Alpha-Mannosidosis", 
                "Mannosidase Deficiency Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject or subjects legally authorized guardian(s) must provide signed, informed\n             consent prior to performing any trial-related activities\n\n          -  The subject and his/her guardian(s) must have the ability to comply with the protocol\n\n          -  The subject must have a confirmed diagnosis of alpha-Mannosidosis as defined by\n             alpha-Mannosidase activity < 10% of normal activity (historical data)\n\n          -  The subject must have an age at the time of screening \u2265 5 years and \u2264 35 years\n\n          -  The subject must have the ability to physically and mentally cooperate in the tests\n\n          -  The subject must have an ECHO without abnormalities that, in the opinion of the\n             Investigator, would preclude participation in the trial\n\n        Exclusion Criteria:\n\n          -  The subjects diagnosis cannot be confirmed by alpha-Mannosidase activity < 10% of\n             normal activity\n\n          -  The subject cannot walk without support\n\n          -  Presence of known chromosomal abnormality and syndromes affecting psychomotor\n             development, other than alpha-Mannosidosis\n\n          -  History of BMT\n\n          -  Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal\n             disease or other medical conditions that, in the opinion of the Investigator, would\n             preclude participation in the trial\n\n          -  Any other medical condition or serious intercurrent illness, or extenuating\n             circumstance that, in the opinion of the Investigator, would preclude participation\n             in the trial\n\n          -  Pregnancy: Pregnant woman is excluded. Before start of the treatment the\n             investigators will for women of childbearing potential perform a pregnancy test and\n             decide whether or not there is a need for contraception\n\n          -  Psychosis; any psychotic disease, also in remission, is an exclusion criteria\n\n          -  Planned major surgery that, in the opinion of the Investigator, would preclude\n             participation in the trial\n\n          -  Participation in other interventional trials testing IMP (including Lamazym) within\n             the last 3 months\n\n          -  Adult patients who, in the opinion of the Investigator, would be unable to give\n             consent, and who does not have any legal protection or guardianship\n\n          -  Total IgE >800 IU/ml\n\n          -  Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681953", 
            "org_study_id": "rhLAMAN-05", 
            "secondary_id": "2012-000979-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lamazym", 
                "description": "ERT, i.v. infusions weekly", 
                "intervention_name": "Lamazym", 
                "intervention_type": "Drug", 
                "other_name": [
                    "rhLAMAN", 
                    "recombinant human alpha-mannosidase"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 5, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "DK-2100"
                    }, 
                    "name": "Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "H\u00f4pital Femme M\u00e8re Enfant, Lyon, 59 boulevard Pinel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "PARIS Cedex 12", 
                        "country": "France", 
                        "zip": "75 571"
                    }, 
                    "name": "H\u00f4pital Trousseau, Service de neurop\u00e9diatrie, Centre R\u00e9f\u00e9rence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Universit\u00e4tsmedizin Mainz, Zentrum f\u00fcr Kinder- und Jugendmedizin, Langenbeckstrasse 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "04 730"
                    }, 
                    "name": "The Children's Memorial Health Institute Warsaw, Department of Metabolic Diseases, Al Dzieci Polskich 20"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M13 9WL"
                    }, 
                    "name": "Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "France", 
                "Germany", 
                "Poland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.", 
        "other_outcome": {
            "description": "Pharmacokinetic (PK) assessments. Blood samples are drawn pre-treatment and at various times post-treatment (see time frame above)", 
            "measure": "Quantitative determination of rhLAMAN in plasma", 
            "safety_issue": "No", 
            "time_frame": "10 min, 60 min, 2 hours, 24 hours, 3 days, 7 days"
        }, 
        "overall_official": [
            {
                "affiliation": "Copenhagen University Hospital, Center for Metabolic Diseases, Department for Clinical Genetics", 
                "last_name": "Allan M Lund, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Zymenex A/S", 
                "last_name": "Jens Fogh", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary efficacy endpoint evaluated as change from baseline in the active group versus the placebo group", 
                "measure": "Reduction of oligosaccharides in serum", 
                "safety_issue": "No", 
                "time_frame": "Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks"
            }, 
            {
                "description": "Primary efficacy endpoint evaluated as change from baseline in the active group versus the placebo group", 
                "measure": "The number of steps climbed in 3 minutes (3-minute stair climb test)", 
                "safety_issue": "No", 
                "time_frame": "Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681953"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary efficacy endpoint evaluated as change from baseline in the active group versus the placebo group", 
                "measure": "Forced Vital Capacity", 
                "safety_issue": "No", 
                "time_frame": "Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks"
            }, 
            {
                "description": "Secondary efficacy endpoint evaluated as change from baseline in the active group versus the placebo group", 
                "measure": "The distance walked in 6 minutes (6-minute walk test)", 
                "safety_issue": "No", 
                "time_frame": "Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks"
            }, 
            {
                "description": "Safety endpoint assessed weekly throughout the trial", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoints assessed weekly throughout the trial", 
                "measure": "Development of clinically significant changes in vital signs and change in physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoints assessed weekly throughout the trial", 
                "measure": "Clinical laboratory parameters (hematology, biochemistry and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoints assessed weekly throughout the trial", 
                "measure": "Development of Lamazym antibodies and neutralizing/inhibitory antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "source": "Zymenex A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "European Commission", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Zymenex A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}